Leucine-restricted diet with chemotherapy for advanced stomach cancer
Part of Cancer, Digestive system clinical trials.
This study tests whether a special diet low in leucine (an amino acid) combined with chemotherapy and immunotherapy can safely treat advanced stomach cancer that has spread. Researchers want to see if this dietary approach helps the treatment work better and reduces side effects.
Summary written for real people, not researchers, by Clin2.
Who can take part
- Advanced stomach cancer that has spread to other parts of your body, confirmed by imaging scans
- Age 18 to 70 years old
- Able to eat by mouth or receive nutrition through a feeding tube
- No other active cancers besides stomach cancer
- Willing to follow a special low-leucine diet throughout the study
- No severe digestive problems like chronic diarrhea, vomiting, or bowel blockages
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests whether a special diet low in leucine (an amino acid) combined with chemotherapy and immunotherapy drugs can help treat locally advanced gastric cancer before surgery. The goal is to see if this combination is safe and more effective than standard treatment alone.
This trial tests if a diet low in leucine (an amino acid) can help treat gastric cancer before surgery. It aims to see if it's safe and effective for patients who are preparing for tumor removal.
This trial tests a combination of low-dose radiation, chemotherapy, and an immunotherapy drug (AK112) for people with advanced stomach or gastroesophageal junction cancer that has progressed after first-line treatment. The goal is to see if this combination can help shrink tumors or slow the cancer's growth.
This trial tests whether adding leucine (a simple amino acid) to standard chemoradiation before surgery can help shrink rectal cancer and improve outcomes. It is for people with locally advanced rectal cancer that hasn't yet spread to other organs.
This trial compares two types of chemotherapy with or without an immunotherapy drug (tislelizumab) for advanced stomach or gastroesophageal junction cancer. It aims to see which combination works better and has fewer side effects.
This trial tests whether adding two newer drugs (pucotenlimab and lenvatinib) to standard chemotherapy (SOX) works better than chemotherapy alone for people with advanced stomach or gastroesophageal junction cancer that is HER2-negative. The goal is to see if the combination slows cancer growth.
Hear when a new Advanced Gastric Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.